Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause

Bibliography

• Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996;11:1043-51
   PubMed Web of Science ®Google Scholar
• Riggs BL, Khosla S, Melton LJ III. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998;13:763-73
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Kosla S, Dunstan CR, et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12
   PubMed Web of Science ®Google Scholar
• Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress RANK ligandinduced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci USA 2000;97:7829-34
   PubMed Web of Science ®Google Scholar
• Hedlund LR, Gallagher JC, Meeger C, et al. Change in vertebral shape in spinal osteoporosis. Calcif Tissue Int 1989;44(3):168-72
   PubMed Web of Science ®Google Scholar
• Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999;353(9152):571-80
   PubMed Web of Science ®Google Scholar
• Gamsjaeger S, Brozek W, Recker R, et al. Transmenopausal changes in trabecular bone quality. J Bone Miner Res 2013; Epub ahead of print
   Web of Science ®Google Scholar
• Guglielmi G, Scalzo G. Imaging tools transform diagnosis of osteoporosis. Diagn Imaging Eur 2010;26:7-11
   Google Scholar
• Santoro N. Symptoms of menopause: hot flushes. Clin Obstet Gynecol 2008;51(3):539-48
   PubMed Web of Science ®Google Scholar
• Avis ND, Stellato R, Crawford S, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med 2001;52:345-56
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304(15):1684-92
   PubMed Web of Science ®Google Scholar
• Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299(9):1036-45
   PubMed Web of Science ®Google Scholar
• Stovall DW, Utian W, Gass M, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007;14:510-17
   PubMed Web of Science ®Google Scholar
• Davis SR, O'Neill SM, Eden J, et al. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium: a pilot study. Menopause 2004;11:167-75
   PubMed Web of Science ®Google Scholar
• Carranza-Lira S, Gooch AL, Saldivar N, et al. Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses. Int J Fértil Womens Med 2007;52:93-6
   PubMedGoogle Scholar
• Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525-35
   PubMed Web of Science ®Google Scholar
• Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-34
   PubMed Web of Science ®Google Scholar
• Miller CP, Collini MD, Tran BD, et al. Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem 2001;44:1654-7
   PubMed Web of Science ®Google Scholar
• Ermer J, McKeand W, Sullivan P, et al. Bazedoxifene acetate dose proportionality in healthy postmenopausal women. Clin Pharmacol Ther 2003;73:46
   Web of Science ®Google Scholar
• Patat A, McKeand W, Baird-Bellaire S, et al. Absolute/relative bioavailability of bazedoxifene acetate in health postmenopausal women. Clin Pharmacol Ther 2003;73:43
   Web of Science ®Google Scholar
• Chandrasekaran A, Ermer J, McKeand W, et al. Bazedoxifene acetate metabolic disposition in healthy postmenopausal women. Clin Pharmacol Ther 2003;73:47
   Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kagan R, et al. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens (BZA/CE) for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045-52
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Utian WH, Constantine GD. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16(6):1116-24
   PubMed Web of Science ®Google Scholar
• Utian WH, Yu H, Bobula J, et al. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas 2009;63:329-35
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Pan K, Abraham L, et al. Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial. Menopause 2013; [Epub ahead of print]
   Web of Science ®Google Scholar
• Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999-4008
   PubMed Web of Science ®Google Scholar
• Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann NY Acad Sci 2001;949:317-26
   PubMed Web of Science ®Google Scholar
• Crabtree JS, Peano BJ, Zhang X, et al. Activity of three selective estrogen receptor modulators on hormone dependent responses in the mouse uterus and mammary gland. Mol Cell Endocrinol 2008;287:40-6
   PubMed Web of Science ®Google Scholar
• Kharode Y, Bodine PVN, Miller CP, et al. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149:6084-91
   PubMed Web of Science ®Google Scholar
• Peano BJ, Crabtree JS, Komm BS, et al. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009;150:1897-903
   PubMed Web of Science ®Google Scholar
• Archer DF, Lewis V, Carr BR, et al. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039-44
   PubMed Web of Science ®Google Scholar
• Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018-24
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, et al. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens (BZA/CE) for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17:281-9
   PubMed Web of Science ®Google Scholar
• Nastri CO, Lara LA, Ferriani RA, et al. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2013;6:CD009672
   Google Scholar
• Mirkin S, Komm BS, Pan K, et al. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric 2013;16(3):338-46
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Harvey JA, Pan K, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol 2013;121(5):959-68
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92(3):1025-38
   PubMed Web of Science ®Google Scholar
• Clarkson TB, Ethun KF, Pajewski NM. Effects of bazedoxifene, conjugated equine estrogens, and a tissue-selective estrogen complex containing both bazedoxifene and conjugated equine estrogens on cerebral artery atherosclerosis in postmenopausal monkeys. Menopause 2013; Epub ahead of print
   Google Scholar
• Clarkson TB, Ethun KF, Chen H. Effects of bazedoxifene alone and with conjugated equine estrogens on coronary and peripheral artery atherosclerosis in postmenopausal monkeys. Menopause 2013;20(3):274-81
   PubMed Web of Science ®Google Scholar
• Palacios S, de Villiers TJ, Nardone Fde C. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study. Maturitas 2013;76(1):81-7
   PubMed Web of Science ®Google Scholar
• Wattanakumtornkul S, Chichareon S, Geater A, et al. Compliance with hormone replacement therapy at Songklanagarind Hospital. J Obstet Gynaecol Res 2003;29:380-7
   PubMed Web of Science ®Google Scholar
• Manonai J, Theppisai U, Suchartwatnachai C, et al. Compliance with hormone replacement therapy in Thai women. Maturitas 2003;44:201-5
   PubMed Web of Science ®Google Scholar
• Archer DF, Dorin M, Lewis V, et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080-7
   PubMed Web of Science ®Google Scholar
• Stovall DW. Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms. Curr Opin Investig Drugs 2010;11(4):464-71
   PubMedGoogle Scholar
• North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:25-54
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol 2009;27:2831-7
   PubMed Web of Science ®Google Scholar
• Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788-93
   PubMed Web of Science ®Google Scholar
• Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057-71
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:355-69
   PubMed Web of Science ®Google Scholar
• Utian WH, Archer DF, Bachmann GH, et al. Estrogen and progestogen use in postmenopausal women: july 2008 position statement of The North American Menopause Society. Menopause 2008;15:584-602
   PubMed Web of Science ®Google Scholar
• Pluchino N, Cubeddu A, Giannini A, et al. Progestogens and brain: an update. Maturitas 2009;62:349-55
   PubMed Web of Science ®Google Scholar
• Bitzer J. Progesterone, progestogens and psychosomatic health of the climacteric woman. Maturitas 2009;62:330-3
   PubMed Web of Science ®Google Scholar
• Goletiani NV, Keith DR, Gorsky SJ. Progesterone: review of safety for clinical studies. Exp Clin Psychopharmacol 2007;15:427-44
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Harris ST, Bone H, et al. Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. Am Fam Physician 2000;61(9):2731-6
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-57
   PubMed Web of Science ®Google Scholar
• Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 2000;152:950-64
   PubMed Web of Science ®Google Scholar
• Kharode Y, Bodine PVN, Miller CP, et al. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149:6084-91
   PubMed Web of Science ®Google Scholar